What the FDA labels say about taking them together
Buprenorphine/naloxone and glecaprevir/pibrentasvir
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names buprenorphine/naloxone in its drug interactions section; the buprenorphine/naloxone labels PlainMeds reads (3) do not name glecaprevir/pibrentasvir. The glecaprevir/pibrentasvir label: “See Clinical Pharmacology, Tables 10 and 11. ↑= increase; ↓= decrease; ↔ = no effect 7.4 Medication-Assisted Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required …”
Check it at the source: the buprenorphine/naloxone FDA label on DailyMed (effective July 26, 2026, Hikma Pharmaceuticals USA Inc.); the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.).
What does the buprenorphine/naloxone label say about glecaprevir/pibrentasvir?
Buprenorphine/naloxone's label (effective July 26, 2026) and its 2 other brand-application labels do not name glecaprevir/pibrentasvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (buprenorphine and naloxone), Hikma Pharmaceuticals USA Inc., effective July 26, 2026 (SPL set 713db2c6-0544-4633-b874-cfbeaf93db89), via openFDA; the full label on DailyMed
What does the glecaprevir/pibrentasvir label say about buprenorphine/naloxone?
Glecaprevir/pibrentasvir label, drug interactionsSee Clinical Pharmacology, Tables 10 and 11 . ↑= increase; ↓= decrease; ↔ = no effect 7.4 Medication-Assisted Treatment (MAT) for Opioid Use Disorder No buprenorphine/naloxone or methadone dosage adjustment is required when used concomitantly with MAVYRET.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Buprenorphine/naloxone | Glecaprevir/pibrentasvir | |
|---|---|---|
| Labeled for | Opioid use disorder | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.521 per tablet 2-0.5 mg sl tablet | $152.98 per tablet 100-40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once